Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls

• Barclays upgraded Oscar Health (OSCR) to Overweight from Equal Weight with a terms people of $35, up from $30. The steadfast says that with "single-line exposure" to the idiosyncratic Affordable Care Act market, Oscar offers the "most nonstop leverage to a imaginable multi-year aggregate re-rating."

• Evercore ISI upgraded Devon Energy (DVN) to Outperform from In Line with a $54 terms target. The better-than-expected mid-month update underscores not conscionable improving superior efficiency, but besides a "surprise, explicit remark connected the portfolio review, with the cardinal connection being 'expeditiously'," the steadfast tells investors.

• JPMorgan upgraded Illumina (ILMN) to Overweight from Neutral with a terms people of $185, up from $125. JPMorgan cites Illumina's lawsuit "stickiness" and its favorable caller lawsuit survey for the upgrade.

• UBS upgraded BorgWarner (BWA) to Buy from Neutral with a terms people of $95, up from $61. The institution is the champion positioned car supplier to payment from non-auto opportunities, the steadfast tells investors successful a probe note.

• UBS upgraded Cava Group (CAVA) to Buy from Neutral with a terms people of $90, up from $85. The institution offers an charismatic same-store-sales catalyst way with industry-leading portion growth, the steadfast tells investors successful a probe note.

Top 5 Downgrades:

• RBC Capital downgraded Nike (NKE) to Sector Perform from Outperform with a terms people of $50, down from $70. While the company's turnaround nether CEO Elliott Hill is making progress, it is "slower and narrower" than expected, the steadfast tells investors successful a probe note.

• Guggenheim downgraded Nuvalent (NUVL) to Neutral from Buy with a terms people of $124, down from $151, citing the projected acquisition by GSK (GSK) for $124 per stock successful an all-cash transaction. UBS, TD Cowen, Barclays, and Truist besides downgraded Nuvalent to Neutral-equivalent ratings.

• Berenberg downgraded Nutrien (NTR) to Hold from Buy with a terms people of $65, up from $61. The institution is apt to present different twelvemonth of coagulated earnings, but the steadfast is acrophobic that statement estimates "will proceed to anchor connected net levels that stay supra mid-cycle."

• Wolfe Research downgraded Taylor Morrison (TMHC) to Peer Perform from Outperform without a terms people pursuing the announced acquisition by Berkshire Hathaway (BRK.A) for $72.50 per share.

• Truist downgraded Bill (BILL) to Hold from Buy with a terms people of $35, down from $45. The steadfast finds it progressively improbable that a software-as-a-service institution similar Bill volition beryllium acquired fixed the uncertainty caused by AI.